Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,253 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals.
Tijms BM, Gobom J, Teunissen C, Dobricic V, Tsolaki M, Verhey F, Popp J, Martinez-Lage P, Vandenberghe R, Lleó A, Molinuévo JL, Engelborghs S, Freund-Levi Y, Froelich L, Bertram L, Lovestone S, Streffer J, Vos S, Adni, Blennow K, Scheltens P, Zetterberg H, Visser PJ. Tijms BM, et al. Among authors: scheltens p. Proteomes. 2021 Aug 2;9(3):36. doi: 10.3390/proteomes9030036. Proteomes. 2021. PMID: 34449748 Free PMC article.
Biomarkers for Alzheimer's disease. Which way to go?
Teunissen CE, Scheltens P. Teunissen CE, et al. Among authors: scheltens p. Neurobiol Aging. 2004 Jul;25(6):695-6. doi: 10.1016/j.neurobiolaging.2003.08.013. Neurobiol Aging. 2004. PMID: 15165690 No abstract available.
Use of proteomic approaches to identify disease biomarkers.
Teunissen CE, Scheltens P. Teunissen CE, et al. Among authors: scheltens p. Lancet Neurol. 2007 Dec;6(12):1036-7. doi: 10.1016/S1474-4422(07)70276-4. Lancet Neurol. 2007. PMID: 18031700 No abstract available.
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.
Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Bürger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K. Visser PJ, et al. Among authors: scheltens p. Lancet Neurol. 2009 Jul;8(7):619-27. doi: 10.1016/S1474-4422(09)70139-5. Epub 2009 Jun 10. Lancet Neurol. 2009. PMID: 19523877
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K. Mattsson N, et al. Among authors: scheltens p. JAMA. 2009 Jul 22;302(4):385-93. doi: 10.1001/jama.2009.1064. JAMA. 2009. PMID: 19622817
Can novel therapeutics halt the amyloid cascade?
Prins ND, Visser PJ, Scheltens P. Prins ND, et al. Among authors: scheltens p. Alzheimers Res Ther. 2010 Apr 9;2(2):5. doi: 10.1186/alzrt28. Alzheimers Res Ther. 2010. PMID: 20388189 Free PMC article.
Association between white matter hyperintensities and executive decline in mild cognitive impairment is network dependent.
Jacobs HI, Visser PJ, Van Boxtel MP, Frisoni GB, Tsolaki M, Papapostolou P, Nobili F, Wahlund LO, Minthon L, Frölich L, Hampel H, Soininen H, van de Pol L, Scheltens P, Tan FE, Jolles J, Verhey FR. Jacobs HI, et al. Among authors: scheltens p. Neurobiol Aging. 2012 Jan;33(1):201.e1-8. doi: 10.1016/j.neurobiolaging.2010.07.015. Epub 2010 Aug 23. Neurobiol Aging. 2012. PMID: 20739101
1,253 results